Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 130 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MmDYR5l1d3SxeHnjJGF{e2G7 NE\IT2EyOCCwTR?= MkS0O|IhcA>? M4LSOmROW09? NY\uTlFYWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NV24fmRNOjR7MEC4O|M>
HT-29 NFqz[4ZEgXSxdH;4bYMhSXO|YYm= MXyxNEBvVQ>? NYLieGlSPzJiaB?= M{TYNGROW09? M33mXHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= NYnxXGN1OjR7MEC4O|M>
HT-29 MXnDfZRwfG:6aXOgRZN{[Xl? M17lWFExKG6P Ml[2O|IhcA>? NYfuN5ZYTE2VTx?= NITSbnhRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NX3GVmVDOjR7MEC4O|M>
PC3 NFXOenpMcW6jc3WgRZN{[Xl? NInXO|EyODBibl2= NIrjcHcyKGh? MYfEUXNQ MlzUVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= MYCyNVk4QDZ6Mx?=
PC3 MYTLbY5ie2ViQYPzZZk> MnvmNVAxKG6P NX7LNlRqOSCq NWf4RYdCTE2VTx?= MXLEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIfxfWkzOTl5OE[4Ny=>
PC3 NHLWNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tbVMyNjVizszN NX71[4oyOSCq MkjxSG1UVw>? MXfJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? MYCyNVk4QDZ6Mx?=
HEK293 M{LmcmZ2dmO2aX;uJGF{e2G7 M{T3c|ExOCCwTR?= M{\rVVghcA>? MVPEUXNQ MXHJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? Ml\rNlE2Ozl|MEG=
BT-20 MnfDT4lv[XOnIFHzd4F6 M4T6RVIxKM7:TR?= Mn7mSG1UVw>? NH;VOGhFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MYGyNVM2OzV3MR?=
U937 NGDp[pdCdnSrYnHjeIVzcWGuIFHzd4F6 NVfKUIx[PTBizszN MXi0PEBp NILOR5JFVVOR MlLWTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MkHjNlEyPDJzME[=
U937 NVTQflY{SW62aXLhZ5RmemmjbDDBd5NigQ>? NGXDXGI2OCEQvF2= NG\obIM1QCCq MlfYSG1UVw>? MlXQSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MmL5NlEyPDJzME[=
U937 NXfoeXJkSW62aXLhZ5RmemmjbDDBd5NigQ>? NULyRnBmPTBizszN NFPPWoQ1QCCq Mke1SG1UVw>? NEjxWYZFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? MYWyNVE1OjFyNh?=
MCF-7 MkG1RZV1d3CqYXf5JGF{e2G7 NIHBTmM{OCCwTR?= NVLjNXBbPCCq MX\EUXNQ M2\ofGlv\HWlZYOgZZV1d3CqYXf5 MYSyNFAzQDF|NB?=
U87MG MW\LbY5ie2ViQYPzZZk> NXzr[3p2OSEQvF2= MoD1OkBp M2jFSWROW09? M2jK[XBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w M3qzSFE6QDR6NEC0
U87MG NYfZeXUyU2mwYYPlJGF{e2G7 MkHJNUDPxE1? NYjKV2UxPiCq M4DwdGROW09? M2PifHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u NYfpXG5XOTl6NEi0NFQ>
U87MG NFS0XWxMcW6jc3WgRZN{[Xl? NX3m[nIyOSEQvF2= MVS2JIg> MV3EUXNQ MU\Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MVuxPVg1QDRyNB?=
U87MG M{jENmtqdmG|ZTDBd5NigQ>? M3\GcFEh|ryP MnuyOkBp MnLJSG1UVw>? M1vuN2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NIizPIYyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb NUTxWWZWSXW2b4DoZYd6KEG|c3H5 Ml;TNE4zKM7:TR?= NET3dZkzPCCq NXXle|JyTE2VTx?= MlnpTY5lfWOnczDheZRweGijZ4m= M2r5elE5OzlzOUS5
COS7 cells expressing EGFP-LC3 M{D4emF2fG:yaHHnfUBCe3OjeR?= MYewMlIh|ryP NVLGcWZwOjRiaB?= NHvKemJFVVOR M136bWlv\HWlZYOgZZV1d3CqYXf5 MXGxPFM6OTl2OR?=
H4 NH;vS4dHfW6ldHnvckBCe3OjeR?= MX6wMlIh|ryP MlHXNlQhcA>? MoGySG1UVw>? M4\qU2lv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> MlvONVgxOjR3OES=
HeLa MoKwSpVv[3Srb36gRZN{[Xl? MXexNFAhdk1? NIC4U2o{PiCq Mn7ySG1UVw>? NYXQdWR2UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? MkLjNVc2PjN|OEW=
HeLa MUTGeY5kfGmxbjDBd5NigQ>? NI\ZcFcyODBibl2= NV6xVHB4OzZiaB?= NGLlTWVFVVOR NXvpPZVOUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MWqxO|U3OzN6NR?=
HeLa M37X[mZ2dmO2aX;uJGF{e2G7 NITncZYyODBibl2= NEfWW3Y{PiCq MV\EUXNQ MYTJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M4\mVlE4PTZ|M{i1
SYF MVHGeY5kfGmxbjDBd5NigQ>? MX6xNFAhdk1? M{j0UVI1KGh? NVTVUFA6TE2VTx?= MlTGTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NHfMeG0yPzV4M{O4OS=>
SYF Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxNFAhdk1? MljUNlQhcA>? NGTxWmZFVVOR NYrBW25uUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M1nsS|E4PTZ|M{i1
HEK293T MVXBcpRqfmm{YXygRZN{[Xl? MnLmNUBvVQ>? MYC0JIQ> MVPEUXNQ M4PPWmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N NG\QS|UyPzR6NUWwNS=>
HEK293T NH\EZ4VCdnSrdnnyZYwhSXO|YYm= MkjxNUBvVQ>? M1\jTFQh\A>? MlLISG1UVw>? NFPYVIdKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MVyxO|Q5PTVyMR?=
PBMC MoHVSpVv[3Srb36gRZN{[Xl? NFPaV4QyKG6P M2nzWFE1KGR? M33MfGROW09? M{\tUXJm\HWlZYOgR2NTPSCmZX7zbZR6 MX[xO|Q5PTVyMR?=
PBMC NETDdmNHfW6ldHnvckBCe3OjeR?= MWWxJI5O MX6xOEBl NGfnVGRFVVOR MlfySI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> MmLSNVc1QDV3MEG=
HEK293 cells MnKxT4lv[XOnIFHzd4F6 NHnxS5g2OCCwTR?= M3vNeVQ2KG2rbh?= MUjEUXNQ MkjJTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? M4TGSVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MkXxSpVv[3Srb36gRZN{[Xl? NGe4c4cyODBibl2= MUW0JIg> NX7jb2VETE2VTx?= NGfDc45KdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? Mn64NVcyOjh{NkK=
Human mixed lymphocyte MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS1JI5O MofQSG1UVw>? NITnZmpKSzVyPUGuOkBvVS5? NIrwXnYyPjF6NUi2OS=>
Lewis rat lymph node cells NHTldXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XaZ|Uh|ryP Mn[0SG1UVw>? Ml\OTWM2OD1{Lk[g{txO NWHLUGUzOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjNVAhdk1? Ml7tO|IhcA>? NWXwUplFTE2VTx?= M3\NdmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= NUDDZ5lkOTByMkG5OFg>
MRK-nu-1 NX76TpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LJR2lEPTB;MD64OFUheE1? MkDDV2FPT0WU
OCUB-M NWPxdW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z2dGlEPTB;NT6yOEBxVQ>? NYLMNHlkW0GQR1XS
SF539 NWS4N5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFzLk[gdG0> MYfTRW5ITVJ?
ES4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD1{MT61JJBO NV[xfnNmW0GQR1XS
RL95-2 NInnTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYni[pZMUUN3ME2xNFcheE1? Mn3EV2FPT0WU
LC-2-ad MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHyTWM2OD12MkOgdG0> NF;4OpRUSU6JRWK=
Daudi NFznU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfybZlKSzVyPUSzOEBxVQ>? NULQNJFSW0GQR1XS
NTERA-S-cl-D1 NXmzTIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVToN[UUN3ME20OFMheE1? NV7kZZRPW0GQR1XS
OS-RC-2 NGPaPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjsbI9KSzVyPU[1NkBxVQ>? NGnsT3NUSU6JRWK=
VA-ES-BJ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HrO2lEPTB;N{KzJJBO MoLJV2FPT0WU
GR-ST M{DZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn74TWM2OD16NE[gdG0> NXqwXlZDW0GQR1XS
SW872 NE\LU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvzO2VKSzVyPUi0OkBxVQ>? NEXIW2ZUSU6JRWK=
NOS-1 NUjOc4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTh5MTDwUS=> MYrTRW5ITVJ?
MC116 NWfuPG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G0ZWlEPTB;OUi1JJBO MlzMV2FPT0WU
NCI-H1355 NHm2dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17rfmlEPTB;MT6wNUBvVQ>? MUPTRW5ITVJ?
RPMI-8226 NVy5PXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X4dGlEPTB;MT6xPUBvVQ>? MmHPV2FPT0WU
TE-15 M1PmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnLd3VKSzVyPUGuN|Yhdk1? MmraV2FPT0WU
Ramos-2G6-4C10 NIXZZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1eGlEPTB;MT60OkBvVQ>? NEnqVHJUSU6JRWK=
KU812 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwMEGgcm0> Mmf1V2FPT0WU
EW-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy0W2NKSzVyPUKuNVchdk1? MlfhV2FPT0WU
KS-1 M1L0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwNEWgcm0> MoW1V2FPT0WU
SK-LMS-1 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHkXYtKUUN3ME2yMlQ6KG6P MV\TRW5ITVJ?
TGBC1TKB NUiyZZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;xTWM2OD1{Lk[5JI5O NED5PYtUSU6JRWK=
TE-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W0eWlEPTB;Mj63O{BvVQ>? MXjTRW5ITVJ?
ETK-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO2e2hVUUN3ME2yMlgzKG6P NWjudJZkW0GQR1XS
BE-13 NU\LUotrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwOUmgcm0> MVjTRW5ITVJ?
A3-KAW M1zkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwOUmgcm0> NIX3PXdUSU6JRWK=
TE-10 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTmWVFbUUN3ME2zMlMhdk1? MWjTRW5ITVJ?
DOHH-2 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPDTWM2OD1|LkO1JI5O NH7mfm9USU6JRWK=
ES6 NX;nfVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W1UGlEPTB;Mz60N{BvVQ>? Mn\3V2FPT0WU
OPM-2 NWTQe3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zLXmlEPTB;ND6xOUBvVQ>? MUfTRW5ITVJ?
SH-4 M1uzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPS[3V6UUN3ME20MlM1KG6P MVfTRW5ITVJ?
NB13 NEflRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vNbWlEPTB;ND6zOkBvVQ>? MWTTRW5ITVJ?
HUTU-80 NETEWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVryPHI4UUN3ME20MlQzKG6P MUTTRW5ITVJ?
CCRF-CEM NUfweJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL1[lFKSzVyPUSuPVQhdk1? NYjzR4NOW0GQR1XS
TGBC24TKB MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqyTWM2OD13LkWxJI5O NGrlR3FUSU6JRWK=
697 M1\kZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwMkigcm0> NX;1fmo1W0GQR1XS
J-RT3-T3-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rtT2lEPTB;Nj60OkBvVQ>? MYPTRW5ITVJ?
KALS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXNTWM2OD14LkW2JI5O Ml:0V2FPT0WU
no-10 M3zJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PZ[mlEPTB;Nz6yPUBvVQ>? NHHYNm5USU6JRWK=
SK-NEP-1 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvqTWM2OD16Lke5JI5O MYjTRW5ITVJ?
L-540 NWHiSJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLCR|BDUUN3ME2xNE41OiCwTR?= MUHTRW5ITVJ?
JiyoyeP-2003 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDvUIJiUUN3ME2xNE46PCCwTR?= MVnTRW5ITVJ?
HH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WxNWlEPTB;MUGuN|khdk1? M2nj[HNCVkeHUh?=
SR MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\FTWM2OD1zMT60OUBvVQ>? NUDXSm9VW0GQR1XS
QIMR-WIL NUnO[Y9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzLki1JI5O Mk\wV2FPT0WU
A4-Fuk NYLV[Wc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7wbFVJUUN3ME2xN{4yOiCwTR?= NE\WNpBUSU6JRWK=
CESS NEjrRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF|LkGzJI5O M12wc3NCVkeHUh?=
KE-37 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnHWGdKSzVyPUG2MlA4KG6P MUDTRW5ITVJ?
SK-UT-1 M4ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF4LkixJI5O NYLCVGdjW0GQR1XS
SIG-M5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf6SndKSzVyPUG3MlI2KG6P NX:4VJl4W0GQR1XS
HT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;XO2lQUUN3ME2xO{43KG6P M4jrOHNCVkeHUh?=
DEL M3T4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPVd4xKSzVyPUG3Mlk6KG6P NXXYfZVxW0GQR1XS
SK-PN-DW MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GyeGlEPTB;MkCuNlMhdk1? M37QR3NCVkeHUh?=
RPMI-8402 M4T6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJzLke3JI5O NIX5PYxUSU6JRWK=
RPMI-6666 M{fRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\vTWlEPTB;MkSuOFIhdk1? NYC1R|BmW0GQR1XS
NCI-H720 NXHMTnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TUfGlEPTB;MkWuOFEhdk1? M1\rTHNCVkeHUh?=
EW-16 NGriW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fs[2lEPTB;Mk[uPFchdk1? M3XHTHNCVkeHUh?=
BL-70 NYfWZXBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfXTWM2OD1{OD6zPEBvVQ>? NY\QW|VRW0GQR1XS
SF126 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LCb2lEPTB;M{CuN|ghdk1? MYHTRW5ITVJ?
BC-1 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lbFI6UUN3ME2zNU4zPiCwTR?= MmDGV2FPT0WU
MHH-PREB-1 M2fVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL1VnZNUUN3ME2zNk41PCCwTR?= M3rNUHNCVkeHUh?=
A101D NWfyR2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XVNWlEPTB;M{KuOlIhdk1? MnjVV2FPT0WU
NMC-G1 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxSmlEPTB;M{OuOlchdk1? M1\jU3NCVkeHUh?=
LB1047-RCC NEHsNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn2e5RKSzVyPUO0MlY6KG6P MmTaV2FPT0WU
EM-2 M{\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN6LkWzJI5O MoWzV2FPT0WU
COLO-684 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnsOpdHUUN3ME2zPU45KG6P NF\pRVdUSU6JRWK=
Becker MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L6d2lEPTB;NEGuNFUhdk1? NVz4[Fg4W0GQR1XS
BL-41 NFPoO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G2PWlEPTB;NEOuOlYhdk1? NFLpcYRUSU6JRWK=
MDA-MB-134-VI NXXQemRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTR2LkCyJI5O NFfJNoxUSU6JRWK=
L-363 NXnXTm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lte2lEPTB;NESuO|Mhdk1? NEL2XHFUSU6JRWK=
ECC4 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DDWGlEPTB;NESuO|ghdk1? MX3TRW5ITVJ?
A388 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR2LkiyJI5O Mlm1V2FPT0WU
HEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13PSGlEPTB;NEmuO|khdk1? M{PMfHNCVkeHUh?=
RKO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzBSJJKSzVyPUWwMlI6KG6P NGmzdnFUSU6JRWK=
KINGS-1 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknnTWM2OD13MT61OUBvVQ>? NHPCU2pUSU6JRWK=
EB-3 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTV{Lk[3JI5O NUj5eG9IW0GQR1XS
ARH-77 NVvHRmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXhfnVKSzVyPUWyMlghdk1? M2XUOXNCVkeHUh?=
GCIY NIfrV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS0bZlKSzVyPUWzMlQ3KG6P NUXC[41wW0GQR1XS
NCI-H1304 NVLTZ2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTV5LkKyJI5O MkDiV2FPT0WU
KARPAS-299 NVzUWZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETR[4ZKSzVyPU[xMlgzKG6P M1rxVnNCVkeHUh?=
IA-LM NVPYTppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y2S2lEPTB;NkiuNVMhdk1? NE\Se5VUSU6JRWK=
GI-1 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zoTGlEPTB;N{CuN|khdk1? NWHWUJllW0GQR1XS
TE-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfSTWM2OD15Nz6xO{BvVQ>? MWXTRW5ITVJ?
LS-411N MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2U5REUUN3ME23O{42PyCwTR?= M2PxW3NCVkeHUh?=
no-11 NHPN[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfpT5pKSzVyPUizMlI1KG6P NVq3NWg6W0GQR1XS
MV-4-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;WVlRYUUN3ME24N{44OyCwTR?= MYfTRW5ITVJ?
BV-173 NHT3NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2eybGlEPTB;OEOuPVchdk1? M4HxZnNCVkeHUh?=
CMK MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD1O29MUUN3ME24OE4yPiCwTR?= Mm\1V2FPT0WU
LC4-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjoRm1KSzVyPUi2MlczKG6P MXPTRW5ITVJ?
COR-L279 NIS4[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHRTHVNUUN3ME24O{4zPSCwTR?= M3TnW3NCVkeHUh?=
NCI-H209 NU\rdJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzCPYxJUUN3ME24O{41OSCwTR?= MXLTRW5ITVJ?
Raji NFTDfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n1S2lEPTB;OEmuO|Ihdk1? NHLiPYpUSU6JRWK=
LB996-RCC MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvycJBZUUN3ME25N{41OyCwTR?= M3Poc3NCVkeHUh?=
NCI-H526 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEewPZJKSzVyPUmzMlU6KG6P M{PRbXNCVkeHUh?=
KGN M2nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTafGRsUUN3ME25Ok4zQSCwTR?= NYS2OlZCW0GQR1XS
MOLT-4 NHvme2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i1[mlEPTB;OU[uO|khdk1? M3XNZXNCVkeHUh?=
PF-382 NUHwUpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ORXVKSzVyPUm2Mlc6KG6P M{DLfnNCVkeHUh?=
BC-3 NW\ZeHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX60cJJKUUN3ME25PU4yQCCwTR?= NVjRUmZGW0GQR1XS
KARPAS-422 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4TWM2OD1zMEKuNFkhdk1? NEjXZWlUSU6JRWK=
SBC-1 M1\ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTuTWM2OD1zMEeuO|Uhdk1? NXzHcIU{W0GQR1XS
LC-1F M1HXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK1O29KSzVyPUGwPE4xPSCwTR?= NFXNeYJUSU6JRWK=
GB-1 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzXTWM2OD1zMEmuNFIhdk1? Mn[yV2FPT0WU
SNB75 NWHhdWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFzOT62PUBvVQ>? MmnOV2FPT0WU
BB65-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nkTWlEPTB;MUG5Mlk{KG6P NFvnOYtUSU6JRWK=
NCI-N87 NEnJSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jGVmlEPTB;MUKxMlk5KG6P NIXU[IhUSU6JRWK=
IST-MEL1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C1bWlEPTB;MUKyMlM5KG6P NGXkTmpUSU6JRWK=
HOP-62 NU\MZZI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF{Nj64PUBvVQ>? MUjTRW5ITVJ?
ACN MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF2Nj63OUBvVQ>? M4HrR3NCVkeHUh?=
DMS-114 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;sdGlEPTB;MUWwMlY4KG6P MmnMV2FPT0WU
MLMA Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[xOmlEPTB;MUW5Mlg5KG6P NGKwfpZUSU6JRWK=
HT-144 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ZOZhKSzVyPUG2OU41OyCwTR?= NHHUfoZUSU6JRWK=
C2BBe1 M3\6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITldmhKSzVyPUG2O{44PiCwTR?= NGfJ[ZdUSU6JRWK=
L-428 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGxSW52UUN3ME2xO|cvPyCwTR?= NV3qeIpiW0GQR1XS
DU-4475 M1jEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF6Nz62PEBvVQ>? NHPuNZJUSU6JRWK=
CP67-MEL NUj0enRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1zOUmuN|ghdk1? NHXl[GpUSU6JRWK=
MEG-01 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i3VWlEPTB;MkCxMlk3KG6P NHfybYNUSU6JRWK=
IST-SL2 NUHvbFdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHrVndpUUN3ME2yNFgvPjNibl2= NYXtRnpWW0GQR1XS
ES8 NV7VW5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjIRlNXUUN3ME2yNlUvQTRibl2= NGHsU3pUSU6JRWK=
COLO-800 NUX1fFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ|NT6yPEBvVQ>? M1\QfHNCVkeHUh?=
MFH-ino NVm4PHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzGbpNKSzVyPUKzOU45PCCwTR?= MXTTRW5ITVJ?
OVCAR-4 NEG4codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\RU4NQUUN3ME2yN|cvOjRibl2= M{D6SXNCVkeHUh?=
PSN1 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XIc2lEPTB;MkSyMlcyKG6P NXi1VngyW0GQR1XS
EW-12 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3iNWJ5UUN3ME2yOFMvOSCwTR?= NFzBc2lUSU6JRWK=
HCC1599 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ4MT60O{BvVQ>? NEfaN5RUSU6JRWK=
SJSA-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL0dXpKSzVyPUK3NU41PiCwTR?= M4ftb3NCVkeHUh?=
ST486 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jHRWlEPTB;Mkm2MlE1KG6P M1W1fnNCVkeHUh?=
NOMO-1 M{TVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorPTWM2OD1|MECuNlEhdk1? M124[XNCVkeHUh?=
MN-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHnTWM2OD1|MEWuN|Ihdk1? M3TSRXNCVkeHUh?=
HCC1187 NVfudYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD1|MEeuNlUhdk1? M2jX[nNCVkeHUh?=
SW982 NWPySldKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNzND63OUBvVQ>? MkTRV2FPT0WU
LB647-SCLC NX\iOmVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\Vd2lEPTB;M{K4MlcyKG6P NGXiVGZUSU6JRWK=
HC-1 M3jnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnUcXZKSzVyPUOzOU42KG6P NUXuWIFrW0GQR1XS
EHEB NY\kVY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN|Nz61NkBvVQ>? NXrHNXo6W0GQR1XS
TUR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnoTWM2OD1|NkOuPVUhdk1? M3;RPXNCVkeHUh?=
LU-139 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjBTWM2OD1|N{iuNFIhdk1? MVnTRW5ITVJ?
NB1 M13MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzTWM2OD1|OESuOFUhdk1? NYTacplxW0GQR1XS
BB30-HNC Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLyVGRKSzVyPUO4PE4{OiCwTR?= M2foNXNCVkeHUh?=
HAL-01 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj2TWM2OD1|OEmuNlYhdk1? NF34c|VUSU6JRWK=
K5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f4SmlEPTB;NEGxMlM4KG6P NEPHNYlUSU6JRWK=
MZ2-MEL MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRzMz62OEBvVQ>? MY\TRW5ITVJ?
RXF393 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Pt[mlEPTB;NEG2MlQ2KG6P Mm\PV2FPT0WU
NCI-H1648 NXr1WFJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRzNz61N{BvVQ>? MXXTRW5ITVJ?
TE-12 M4r2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13iXmlEPTB;NEO0MlI3KG6P NE\sc4VUSU6JRWK=
EoL-1- M4KzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR|Nz65PEBvVQ>? M3nkZ3NCVkeHUh?=
JAR NXj3SldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3tVZFKSzVyPUSzPE43OiCwTR?= MnvVV2FPT0WU
DSH1 NVnCZXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvCTWM2OD12NUiuPVEhdk1? MWfTRW5ITVJ?
NCI-H187 NEnwWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1b3R7UUN3ME20OlIvQDFibl2= NUDsfol2W0GQR1XS
HCE-4 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR5Nz62OkBvVQ>? M{O1UHNCVkeHUh?=
8-MG-BA NGrh[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfE[5VKSzVyPUW4NU42OiCwTR?= NV76OGRKW0GQR1XS
KLE MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzG[nFuUUN3ME21PFUvOiCwTR?= NVPuNY9EW0GQR1XS
KNS-42 NVjxSIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTV6Nj64NUBvVQ>? M2TCVnNCVkeHUh?=
MSTO-211H MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZyOT63OEBvVQ>? M3\vRXNCVkeHUh?=
GDM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ZZYpKSzVyPU[xOE4xQSCwTR?= NGLMOo5USU6JRWK=
TE-1 NVjoeY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnznTWM2OD14NE[uNVIhdk1? NH3rUYJUSU6JRWK=
BT-474 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTZ2Nz6wOkBvVQ>? NWjle41tW0GQR1XS
KARPAS-45 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGxfXRGUUN3ME22OFcvPiCwTR?= NIjvNZRUSU6JRWK=
MOLT-16 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDvXZNKSzVyPU[0O{46OyCwTR?= NUjhb2s{W0GQR1XS
KURAMOCHI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf3[JpEUUN3ME22OVcvPTFibl2= MkjqV2FPT0WU
K-562 NXTmV2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLuTWM2OD14NkmuOVEhdk1? M4HVXHNCVkeHUh?=
EKVX NUfJPFhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0R2lEPTB;NkeyMlcyKG6P M33ZW3NCVkeHUh?=
GAK M3XWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K4fWlEPTB;Nke1MlMhdk1? NYn3S3d4W0GQR1XS
NCI-SNU-5 M1XYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L4e2lEPTB;NkmwMlAyKG6P NVj6ZWFzW0GQR1XS
NCI-H2126 NY\WfpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDITWM2OD15Mk[uPFchdk1? NYLyRXRoW0GQR1XS
CTV-1 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITmZ3RKSzVyPUe0OE46KG6P MVfTRW5ITVJ?
SW962 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:3TWM2OD15NEiuOFQhdk1? Mn25V2FPT0WU
MONO-MAC-6 NG[y[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD15NU[uPVMhdk1? NXvjWXhxW0GQR1XS
NCI-H748 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP6PIFlUUN3ME23OVgvQTlibl2= MnS1V2FPT0WU
NCI-H524 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfOcYdKSzVyPUe4NE44OyCwTR?= M3W0NXNCVkeHUh?=
LS-123 NYP2TpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3rTWM2OD15OUWuOlkhdk1? NVrZ[Vh3W0GQR1XS
NB7 M1\Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf2TYRKSzVyPUixOE4yPCCwTR?= M3HkOXNCVkeHUh?=
LS-1034 NYq1O4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTh{OD65PEBvVQ>? NWTV[VRkW0GQR1XS
TE-5 NW[5XIdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJVnFKSzVyPUi4N{42PiCwTR?= NHL0UY1USU6JRWK=
A704 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3vTWM2OD16OUmuNVUhdk1? MmnZV2FPT0WU
TK10 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlzNj6wN{BvVQ>? NFnVbpZUSU6JRWK=
NCI-H345 NHzNc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF22XW5KSzVyPUm0N{4zOiCwTR?= MU\TRW5ITVJ?
CGTH-W-1 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTl2OD6xN{BvVQ>? MVTTRW5ITVJ?
NCI-H510A MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTl6NT6xNkBvVQ>? NULUXnhTW0GQR1XS
NCI-H1963 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwMEOyPVIh|ryP NUP1eYZKW0GQR1XS
SCC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DFR2lEPTB;MT6wN|QyPCEQvF2= MkTiV2FPT0WU
EW-11 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUbGpKSzVyPUGuNFg4PDNizszN M3f0bnNCVkeHUh?=
CPC-N NXiz[ZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzYc5JKSzVyPUGuNFg5KM7:TR?= NILLOpFUSU6JRWK=
NCI-H1417 NFHSVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LxTWlEPTB;MT6xNlI3KM7:TR?= NUnaWXF4W0GQR1XS
DG-75 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfoVGFKSzVyPUGuNVYzQDVizszN MlvrV2FPT0WU
HD-MY-Z NUO4bpppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0T2lEPTB;MT6xOlQyPiEQvF2= NVfUOnFOW0GQR1XS
ATN-1 NE\Td5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrERWp3UUN3ME2xMlI3OjB7IN88US=> NXfUcpdbW0GQR1XS
KM-H2 NVjJcJFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2[WlEPTB;MT6yOlQxQCEQvF2= NX\LcXB2W0GQR1XS
NCI-H2081 NYG1[WFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\MNXBOUUN3ME2xMlI3PjN5IN88US=> NIKzWXhUSU6JRWK=
HL-60 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DXTWlEPTB;MT6yOlk2QSEQvF2= MXTTRW5ITVJ?
DB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6XGlEPTB;MT6yO|I1OiEQvF2= Mo\6V2FPT0WU
NCI-H1522 NHPMeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjXmlEPTB;MT6yPFg5PyEQvF2= NWrvNJRVW0GQR1XS
AM-38 NWj1WVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwM{C3NkDPxE1? NYS2bHJbW0GQR1XS
NCI-H446 M2TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y3ZWlEPTB;MT6zNlEzOSEQvF2= MUTTRW5ITVJ?
SU-DHL-1 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLhbG4yUUN3ME2xMlMzQDBzIN88US=> M4jqO3NCVkeHUh?=
NH-12 NFPR[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny0TWM2OD1zLkO2N|c1KM7:TR?= MUHTRW5ITVJ?
DMS-79 NYL1Rmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\hTWM2OD1zLkO2PFY3KM7:TR?= NYP5PZVjW0GQR1XS
NCI-H716 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TpeWlEPTB;MT6zPFk5PiEQvF2= MXLTRW5ITVJ?
ML-2 NIftbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPScGdKSzVyPUGuOFE2OjlizszN NHTHdWRUSU6JRWK=
NB10 M3\rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnFTWM2OD1zLkS2OlMzKM7:TR?= M2nONXNCVkeHUh?=
ONS-76 NEPUe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzTWM2OD1zLkWzOVY6KM7:TR?= NIfnW5ZUSU6JRWK=
LOUCY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\SUXhIUUN3ME2xMlU1PjV5IN88US=> NXv6XlFjW0GQR1XS
SCLC-21H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXLPWJKSzVyPUGuOVg2QDJizszN MoWyV2FPT0WU
TGW M1\EV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET1WZJKSzVyPUGuOlM6PzVizszN MoOwV2FPT0WU
LXF-289 NYG1dYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwN{OyOlgh|ryP MYrTRW5ITVJ?
BB49-HNC NFjhXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7JcVE5UUN3ME2xMlc{PTh4IN88US=> MUDTRW5ITVJ?
NCI-H747 NGnk[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\nRm1KSzVyPUGuO|U{PDZizszN NH72ZnNUSU6JRWK=
LU-165 M4CyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwOES5PFYh|ryP MUPTRW5ITVJ?
OMC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxOVVKSzVyPUGuPVUxPjZizszN NWDkOmVEW0GQR1XS
RCC10RGB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1naPWlEPTB;MT65OVgyPyEQvF2= NH\tfJdUSU6JRWK=
SW684 NVXQeVJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOU[wPVkh|ryP MX7TRW5ITVJ?
TE-8 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMEW1OVkh|ryP M3Pwe3NCVkeHUh?=
SK-N-DZ Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Wb2ZKSzVyPUKuNVMzPzRizszN NHn6fVZUSU6JRWK=
EVSA-T NXL6cWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwMUezNVUh|ryP MXnTRW5ITVJ?
KASUMI-1 NY\nOpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjZflhKSzVyPUKuNVg5OTVizszN MlPCV2FPT0WU
NKM-1 NXH1cZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwMkW0O|Ih|ryP MYLTRW5ITVJ?
CAL-148 NFjlbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2zTWM2OD1{LkOzOlE1KM7:TR?= NWTjVIRYW0GQR1XS
NCI-H64 M4Lqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf2TWM2OD1{LkO0NlMzKM7:TR?= MUDTRW5ITVJ?
KNS-81-FD NWrjUnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTyTWM2OD1{LkO2OlIh|ryP MUDTRW5ITVJ?
KM12 NVvvU2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fEemlEPTB;Mj60NFg{QSEQvF2= MWnTRW5ITVJ?
SW954 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G5emlEPTB;Mj60O|c4QSEQvF2= NH:yUWVUSU6JRWK=
NCI-H1395 NF7nWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwNUK2OFUh|ryP MXvTRW5ITVJ?
DJM-1 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PFRWlEPTB;Mj62NFY{KM7:TR?= MXvTRW5ITVJ?
COLO-668 NFPLbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFVW54UUN3ME2yMlgzPjl3IN88US=> Moq2V2FPT0WU
NCI-H1436 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwOEW2NVUh|ryP MXzTRW5ITVJ?
LB2241-RCC M{DRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwOE[4N|kh|ryP MofVV2FPT0WU
GT3TKB NXjsSVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnpdlhWUUN3ME2yMlg6ODV3IN88US=> NH[2SJBUSU6JRWK=
COLO-824 M4HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmToTWM2OD1{Lki5O|Y5KM7:TR?= NVLt[ZBjW0GQR1XS
ES1 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3z[5dKSzVyPUKuPFk5PzlizszN NHL0UnFUSU6JRWK=
LB771-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzETWM2OD1{LkmwPVQ3KM7:TR?= NUW5ZXY6W0GQR1XS
GI-ME-N M1naOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf4S5dKSzVyPUOuNFA6ODRizszN Moj4V2FPT0WU
NALM-6 NVS2PFFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwMEC5N|Mh|ryP NFX1eWNUSU6JRWK=
LU-134-A NH3YTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMEW0NlUh|ryP NGP6UFJUSU6JRWK=
DMS-153 NUnIOJdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4WY5PUUN3ME2zMlA2QDJ2IN88US=> MYLTRW5ITVJ?
MZ1-PC M3z5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2juS2lEPTB;Mz6wPVA4QCEQvF2= MXvTRW5ITVJ?
NCI-H1155 NF3ZZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7idIFKSzVyPUOuNVE3OSEQvF2= MmXWV2FPT0WU
CAS-1 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;jc2RKSzVyPUOuNVM4ODdizszN MU\TRW5ITVJ?
D-502MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT3PZVKSzVyPUOuNVQ{QSEQvF2= NXzhdpdUW0GQR1XS
NCI-H2141 NUnBSIgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwMUe0OVIh|ryP MUfTRW5ITVJ?
NB6 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwMUiyOVkh|ryP MUjTRW5ITVJ?
NCCIT Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kRmlEPTB;Mz6yNVgxQSEQvF2= MWDTRW5ITVJ?
NB69 NVnBXFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P0OGlEPTB;Mz6zNVg6OSEQvF2= MWPTRW5ITVJ?
JVM-2 NHXRUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwM{[0N|Mh|ryP M4fJTnNCVkeHUh?=
K052 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OzXmlEPTB;Mz6zO|k3QCEQvF2= NWHwNZlOW0GQR1XS
HCC2157 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojrTWM2OD1|LkWzNlI5KM7:TR?= M3zB[XNCVkeHUh?=
KMOE-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzMcoFoUUN3ME2zMlU1OjR{IN88US=> MYXTRW5ITVJ?
SF268 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlywTWM2OD1|LkexOVU1KM7:TR?= MVrTRW5ITVJ?
CHP-126 M1TkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnHU5FvUUN3ME2zMlc3PDV6IN88US=> NIjPXmlUSU6JRWK=
CP66-MEL M3f4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;rTWM2OD1|Lke5NFk1KM7:TR?= NGf2d3hUSU6JRWK=
NCI-H69 M135ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwMEG5N|Yh|ryP NV7sSHg5W0GQR1XS
A253 M17hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq1OoVKSzVyPUSuNFIyODFizszN MUDTRW5ITVJ?
NB14 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorpTWM2OD12LkGwOFc6KM7:TR?= NYT0UGViW0GQR1XS
NCI-H1694 NYTzVpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGybnY4UUN3ME20MlE{OTF{IN88US=> NHjSeHNUSU6JRWK=
NCI-H2196 NFS0RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XlTGlEPTB;ND6xO|E3QSEQvF2= NIXSU3dUSU6JRWK=
TE-9 M4nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDqTJRrUUN3ME20MlE4PTh{IN88US=> NHPrbWlUSU6JRWK=
D-283MED NGTHUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ETWM2OD12LkG4PFQh|ryP M2rzZ3NCVkeHUh?=
OCI-AML2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwMUm0PFkh|ryP NV\weVk5W0GQR1XS
D-263MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nhTWlEPTB;ND6yNlk3OSEQvF2= MYXTRW5ITVJ?
MPP-89 NITYO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37vcmlEPTB;ND6yO|MxPCEQvF2= MXzTRW5ITVJ?
LAMA-84 NHL6OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwM{C0NlEh|ryP MWHTRW5ITVJ?
LB373-MEL-D MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rHXGlEPTB;ND6zOlc5QSEQvF2= NGjHNoNUSU6JRWK=
UACC-257 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH2[mFwUUN3ME20MlM6PTN2IN88US=> MmXCV2FPT0WU
MC-CAR MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C4VmlEPTB;ND60N|k6KM7:TR?= NFXS[nZUSU6JRWK=
COLO-320-HSR NGrSU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwNES0Nlch|ryP NV[5bWhjW0GQR1XS
P30-OHK NITidpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrlTWM2OD12Lk[2OVgyKM7:TR?= MoLsV2FPT0WU
UACC-812 M3jZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHmcoxKSzVyPUSuOlkyPjFizszN Mo\EV2FPT0WU
CTB-1 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kTZNKSzVyPUSuO|E2PTVizszN NWXPN3g{W0GQR1XS
ALL-PO M3nJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nSdmlEPTB;ND64OFA4PyEQvF2= NIT4bGZUSU6JRWK=
SK-MEL-2 M3PuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzxZo5KSzVyPUSuPFY6PTVizszN NUXC[JYxW0GQR1XS
TC-YIK MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfvSoM3UUN3ME20Mlk4QTR{IN88US=> MlLGV2FPT0WU
NCI-H1882 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnmPVJyUUN3ME21MlAzODBzIN88US=> MUXTRW5ITVJ?
MHH-CALL-2 M4XnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojYTWM2OD13LkC1NFQzKM7:TR?= M3O3W3NCVkeHUh?=
U-87-MG NYHROG5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6xbIVEUUN3ME21MlA6PDZ4IN88US=> M{jiSXNCVkeHUh?=
NCI-H1092 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNUXBCUUN3ME21MlI3PTV3IN88US=> NEPzW5JUSU6JRWK=
TE-441-T NXS0e|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\BSmlEPTB;NT6yO|gzKM7:TR?= NXi0T3g5W0GQR1XS
SK-MEL-1 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3NTXpKSzVyPUWuNlkxPDRizszN NYTkeGJbW0GQR1XS
EW-22 M4HCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDCO3I3UUN3ME21MlI6PDZ4IN88US=> NX7SZ|NnW0GQR1XS
MZ7-mel M33LSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7xTG5KSzVyPUWuOFA3QTFizszN NGrPendUSU6JRWK=
LP-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2ZVllUUN3ME21MlQyOjlzIN88US=> MYPTRW5ITVJ?
NCI-SNU-16 NILtOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3[mlEPTB;NT62OFA4PCEQvF2= MXHTRW5ITVJ?
LU-65 NELxSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q5T2lEPTB;NT63OlM4OyEQvF2= NF\RVYRUSU6JRWK=
CW-2 M1y3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\hTWM2OD13Lki1PVU6KM7:TR?= NU\PWYVUW0GQR1XS
WSU-NHL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VTWM2OD13Lkm1NVc1KM7:TR?= NVHwTnM6W0GQR1XS
IST-MES1 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSwPGlWUUN3ME21Mlk2PDR|IN88US=> NWTwdFdrW0GQR1XS
U-266 M1viNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTJOJdKSzVyPUWuPVgzODJizszN NHuxcYNUSU6JRWK=
TALL-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO0bGRDUUN3ME22MlE1Pjh6IN88US=> NHXUT5BUSU6JRWK=
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT5TWM2OD14LkG1N|E3KM7:TR?= NFL3WHVUSU6JRWK=
MMAC-SF M2rEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHryV3RKSzVyPU[uNVg2PTZizszN M4LGZ3NCVkeHUh?=
NCI-H82 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M365SGlEPTB;Nj6yNFQ5QSEQvF2= NEHDVXVUSU6JRWK=
RS4-11 NXzhXIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnCcZJqUUN3ME22MlI2QDl5IN88US=> M2H5dXNCVkeHUh?=
SNU-C2B MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX1TWM2OD14LkSwPVY6KM7:TR?= MXfTRW5ITVJ?
BOKU NE\q[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjZYVKSzVyPU[uOFc2QTdizszN Ml73V2FPT0WU
C8166 M3jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTTWM2OD14LkW1PVEzKM7:TR?= NFjWSJdUSU6JRWK=
D-247MG MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwMESzOFch|ryP NUK1WFFQW0GQR1XS
EW-18 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;MOnNKSzVyPUeuNFczQTJizszN NG\rbWtUSU6JRWK=
KG-1 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PzTGlEPTB;Nz62Nlc{QCEQvF2= NYfvbIsyW0GQR1XS
REH M4LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyTWM2OD15Lk[4NVA6KM7:TR?= M4j1UnNCVkeHUh?=
U-698-M M4ToXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rDZ2lEPTB;Nz64OFMyPSEQvF2= MXnTRW5ITVJ?
KP-N-RT-BM-1 NHLWemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPQTWM2OD15LkmzNFI6KM7:TR?= NV\qT|hWW0GQR1XS
MS-1 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DmPGlEPTB;Nz65OlA1OSEQvF2= NIfqOHFUSU6JRWK=
SNU-C1 M{K4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTdwOUixPVIh|ryP M3nE[XNCVkeHUh?=
SK-MM-2 NILJZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq5ZVdKSzVyPUiuNlYxPjVizszN MWLTRW5ITVJ?
LAN-6 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjNVGNKSzVyPUiuN|AxODFizszN M1vTPXNCVkeHUh?=
NEC8 M{DtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\0TWM2OD16LkOwOlkyKM7:TR?= MWLTRW5ITVJ?
NCI-H1770 NUfaVmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD16LkO4NFAzKM7:TR?= MoTyV2FPT0WU
D-336MG NXuzOYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorZTWM2OD16LkSwNVE3KM7:TR?= MmTFV2FPT0WU
COLO-829 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZbGlEPTB;OD60PFg4QSEQvF2= NYfhOmF2W0GQR1XS
LS-513 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRThwNUm1PVkh|ryP MX3TRW5ITVJ?
YT NYXk[|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\mbZh6UUN3ME24MlYzPDJ5IN88US=> MUHTRW5ITVJ?
EW-24 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiyTmpzUUN3ME24Mlc3PTRizszN M{e4PHNCVkeHUh?=
IST-SL1 NFvIeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRThwOE[1OFMh|ryP MUjTRW5ITVJ?
CA46 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuRmlEPTB;OD65OVA6QCEQvF2= MoPqV2FPT0WU
NCI-H1838 M4fsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfOSFYzUUN3ME24Mlk5PjB{IN88US=> MWnTRW5ITVJ?
NCI-H719 M4fJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwMkWyO|kh|ryP MmDpV2FPT0WU
HCE-T NVnQdYo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTlwM{C4OVEh|ryP MWXTRW5ITVJ?
A498 M3ux[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ZfG1KSzVyPUmuN|YyOjRizszN NUTDZmY1W0GQR1XS
LB831-BLC M3;ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTlwN{[1NlEh|ryP NY[0WYd4W0GQR1XS
SKM-1 NHi5ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTlwOEW5OlMh|ryP M1\IWnNCVkeHUh?=
THP-1 M3Wzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fXUWlEPTB;OT65OlkyQCEQvF2= M{W3[XNCVkeHUh?=
SHP-77 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vqfWlEPTB;MUCuOFA4KM7:TR?= NIPNUo1USU6JRWK=
EW-3 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFyLk[yPFkh|ryP MoHGV2FPT0WU
KY821 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHwN5JEUUN3ME2xNE44PjNizszN MorPV2FPT0WU
NCI-SNU-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGeIdKSzVyPUGxMlAzOTdizszN M{H5b3NCVkeHUh?=
HCC2218 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPlW3FzUUN3ME2xNU4{QTh4IN88US=> MVTTRW5ITVJ?
IM-9 M1PtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFzLkWxNFYh|ryP NVO2bHAxW0GQR1XS
NCI-H889 NY\FT2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfQPJZyUUN3ME2xNU42OzF|IN88US=> NVjkWZloW0GQR1XS
HDLM-2 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4W2lEPTB;MUKuOFE2QSEQvF2= MV\TRW5ITVJ?
LB2518-MEL M13HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkS2hKSzVyPUGyMlY5OTVizszN MmfLV2FPT0WU
NCI-H23 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PkZ2lEPTB;MUOuNlQzPSEQvF2= NYXuTXd5W0GQR1XS
NB17 NH7BbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tVmtKSzVyPUGzMlQ2PzlizszN MoLWV2FPT0WU
NCI-H322M MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF2LkSwOlgh|ryP NGjxPGlUSU6JRWK=
SUP-T1 NHXveXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD1zND60NVMh|ryP M2\oOXNCVkeHUh?=
ES3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorTTWM2OD1zNT6wO|A{KM7:TR?= MUPTRW5ITVJ?
ES5 M{H2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7UOmhKSzVyPUG1MlA4QDdizszN NEj6PJBUSU6JRWK=
NCI-H1650 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;aTWM2OD1zNT60PVc6KM7:TR?= MXHTRW5ITVJ?
NCI-H226 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQR45KSzVyPUG1Mlg4PjhizszN MljhV2FPT0WU
COR-L88 NFfafHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF4LkOxOEDPxE1? NUXVSVI6W0GQR1XS
SCC-15 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJTWM2OD1zNj6zPFY6KM7:TR?= MXjTRW5ITVJ?
GOTO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\KWINKSzVyPUG2MlQ4QTNizszN NGHOZmJUSU6JRWK=
SIMA NI\sRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTTmlEPTB;MU[uOFgxOiEQvF2= NV;Xfm93W0GQR1XS
NCI-H1299 M{TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF5LkG1PVEh|ryP NInP[lNUSU6JRWK=
NCI-H1581 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLPbIpKSzVyPUG3MlQzOTlizszN M2r4ZXNCVkeHUh?=
MHH-NB-11 NV7CTY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETQflFKSzVyPUG3Mlk3QDNizszN NHjSW|hUSU6JRWK=
MFM-223 NF3IOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF6LkC1N|gh|ryP M{\RdHNCVkeHUh?=
ES7 M2KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HiU2lEPTB;MUiuOVQ{OSEQvF2= MYnTRW5ITVJ?
JVM-3 M1\XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTsTWM2OD1zOD63NVch|ryP M2P5cXNCVkeHUh?=
RL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjKSHBKSzVyPUKwMlM5QCEQvF2= NHfCSo1USU6JRWK=
EC-GI-10 NIfiWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJzLkKwOFEh|ryP MVXTRW5ITVJ?
LNCaP-Clone-FGC NVXYS|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Wyc2lEPTB;MkGuOlc3QCEQvF2= MlvGV2FPT0WU
IMR-5 M37JXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rZPWlEPTB;MkGuPFQ6PCEQvF2= NXXLcpRKW0GQR1XS
KP-N-YS NYS2WHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HueGlEPTB;MkGuPFc2KM7:TR?= M1i5TXNCVkeHUh?=
Mo-T NEC4RnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17SfGlEPTB;MkKuNlE5PSEQvF2= MlT2V2FPT0WU
NCI-H128 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojjTWM2OD1{Mz61PFU{KM7:TR?= M3zkeHNCVkeHUh?=
RH-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfL[4NKSzVyPUKzMlc5PjZizszN Mnv2V2FPT0WU
NCI-H2171 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLhZXJWUUN3ME2yOE4zPDh3IN88US=> M2rmfHNCVkeHUh?=
RPMI-8866 NHrLNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTITWM2OD1{Nj63OFIh|ryP NGLJVYpUSU6JRWK=
SK-N-FI NFziemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf4cGhKSzVyPUK3MlM5OTFizszN MmG2V2FPT0WU
LOXIMVI M{HRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfwWoZVUUN3ME2yO{45ODVzIN88US=> NUW2bWx4W0GQR1XS
P31-FUJ MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6SmNKSzVyPUOxMlU{PzRizszN Mn:xV2FPT0WU
KMS-12-PE MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;kTWM2OD12OT61N|AzKM7:TR?= NVTqWlZwW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID